According to the American Porphyria Foundation (APF), EPP and XLP ... including in the UK. The drug accounts for the bulk of the Australian company's revenues, which reached A$95 million ($63 ...

Porphyria. Monitor LFTs, CBCs during long-term therapy. Assess patient's risk for abuse, misuse, addiction prior to and during therapy. Avoid abrupt cessation. Withdraw gradually. Drug or alcohol ...

Porphyria or thyroid dysfunction ... pancreatitis, photosensitivity, drug fever, rash (may be serious, eg, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia ...